Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.52 |
| ▸ | BAD | Q92934 | 1/20 | 0.52 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.37 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.37 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.37 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | NQO1 | P15559 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 5/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6166395 | 0.96 | BCL2L1 (0.47) | BCL2L1BADGRIA1GRIA2GRIA3 | |
| SCHEMBL1284960 | 0.79 | BCL2L1 (0.58) | BCL2L1BADGRIA1GRIA2GRIA3 | |
| SCHEMBL3797823 | 0.77 | BCL2L1 (0.56) | BCL2L1BADGRIA1GRIA2GRIA3 | |
| SCHEMBL19830024 | 0.76 | CES1 (0.41) | BCL2L1BADNOS3NOS1NOS2 | |
| SCHEMBL30778182 | 0.76 | CES1 (0.41) | BCL2L1BADNOS3NOS1NOS2 | |
| SCHEMBL16239399 | 0.75 | BCL2L1 (0.52) | BCL2L1BADGRIA1GRIA2GRIA3 | |
| SCHEMBL15054072 | 0.74 | BCL2L1 (0.52) | BCL2L1BADGRIA1GRIA2GRIA3 | |
| SCHEMBL22102716 | 0.74 | BCL2L1 (0.52) | BCL2L1BADGRIA1GRIA2GRIA3 | |
| SCHEMBL5768853 | 0.74 | BCL2L1 (0.47) | BCL2L1BADGRIA1GRIA2GRIA3 | |
| SCHEMBL11316442 | 0.74 | BCL2L1 (0.52) | BCL2L1BADGRIA1GRIA2GRIA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680226-A2 | ACYLSULFONAMIDE KAT6A INHIBITORS | Olema Pharmaceuticals, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20260015327-A1 | ACYLSULFONAMIDE KAT6A INHIBITORS | OLEMA PHARMACEUTICALS INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12428379-B2 | Acylsulfonamide KAT6A inhibitors | OLEMA PHARMACEUTICALS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20250136553-A1 | ACYLSULFONAMIDE KAT6A INHIBITORS | OLEMA PHARMACEUTICALS, INC. | 2025-05-01 | — | — | US | disclosed |
| WO-2024189598-A2 | ACYLSULFONAMIDE KAT6A INHIBITORS | OLEMA PHARMACEUTICALS, INC. (US) | 2024-09-19 | — | — | WO | disclosed |
| WO-2023078127-A1 | MACROCYCLIC SULFONAMIDE COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 中国药科大学 | 2023-05-11 | — | — | WO | disclosed |
| CN-113195492-B | Novel compound with three-fused ring structure, preparation method and application thereof | 信达生物制药(苏州)有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-113195492-A | Novel compound with three-fused ring structure, preparation method and application thereof | 信达生物制药(苏州)有限公司 | 2021-07-30 | — | — | CN | disclosed |
| EP-1963292-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-7700633-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-04-20 | — | — | US | disclosed |
| WO-2007067615-A2 | THIADIAZOLE DERIVATIVES AS ANTIDIABETIC AGENTS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
| US-6964965-B2 | Substituted pyrazine derivatives | PHARMACIA & UPJOHN (US) | 2005-11-15 | — | — | US | disclosed |
| EP-1499599-A1 | SUBSTITUTED PYRAZINE DERIVATIVES | Pharmacia & Upjohn Company LLC (US) | 2005-01-26 | — | — | EP | disclosed |
| US-20040053941-A1 | Substituted pyrazine derivatives | PHARMACIA & UPJOHN COMPANY | 2004-03-18 | — | — | US | disclosed |
| WO-2003091225-A1 | SUBSTITUTED PYRAZINE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2003-11-06 | — | — | WO | disclosed |
| WO-2000078724-A2 | IMIDAZOLINDERIVATIVES THEIR PREPARATION AND THEIR PHARMACEUTICAL USE | ELI LILLY AND COMPANY (US) | 2000-12-28 | — | — | WO | disclosed |
| US-5418239-A | ACYLCOENZYME A:CHOLESTEROL ACYLTRANSFERASE INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-05-23 | — | — | US | disclosed |
| US-5264454-A | Enzyme inhibitors, anticholesterol agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-11-23 | — | — | US | disclosed |
| EP-0481243-A1 | Tricyclic heterocyclic compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1992-04-22 | — | — | EP | disclosed |
| US-4077962-A | WATER INSOLUBLE, GREEN-YELLOW, SYNTHETIC FIBERS | BAYER AKTIENGESELLSCHAFT (DT) | 1978-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053941-A1 | Substituted pyrazine derivatives | CRHR1, CRHR2, CRH | BCL2L1 4127/4885BAD 2606/4885GRIA1 40/4885 |
| US-20250136553-A1 | ACYLSULFONAMIDE KAT6A INHIBITORS | KAT6A, KAT2A, KAT6B | BCL2L1 3703/4885BAD 4174/4885GRIA1 675/4885 |
| US-12428379-B2 | Acylsulfonamide KAT6A inhibitors | KAT6A, KAT2A, KAT6B | BCL2L1 3703/4885BAD 4174/4885GRIA1 675/4885 |
| US-20260015327-A1 | ACYLSULFONAMIDE KAT6A INHIBITORS | KAT6A, KAT2A, KAT6B | BCL2L1 2398/4885BAD 4218/4885GRIA1 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.